Multivitamin supplementation aims to prevent micronutrient deficiencies in GLP-1 RA weight loss patients

Obesity and related conditions are increasingly treated with GLP-1 RAs (e.g., semaglutide, liraglutide), which induce significant weight loss via appetite suppression and delayed gastric emptying. However, chronic reduced caloric intake from GLP-1 RA use may elevate the risk of micronutrient deficiencies, mirroring issues seen post-bariatric surgery. In metabolic and bariatric surgery (MBS) cohorts, specialized high-dose multivitamin supplementation significantly lowers deficiency incidence. This trial addresses the gap by empirically validating if similar proactive nutrient supplementation benefits individuals undergoing weight loss with GLP-1 RAs.

This randomized trial aims to compare Balanced nutritional tablets-comprehensive multivitamin and mineral supplements against a placebo control over 12 months. The study population consists of patients utilizing GLP-1 RAs for weight loss. The primary objective is to investigate the efficacy of supplementation in preventing micronutrient deficiencies. Researchers will also assess changes in key nutrient biomarkers and relevant clinical outcomes throughout the study duration.

This abstract describes the aim of a randomized controlled trial and does not present any completed findings or specific numerical results. The study is designed to investigate the efficacy of multivitamin supplementation, not to report on its outcomes. Therefore, no specific data, percentages, or p-values are available at this stage. The research is currently in the planning or recruitment phase, with results anticipated upon completion of the 12-month intervention and subsequent analysis.